A Multi-Center Randomized Phase II Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer [CA209-9FC]
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Aug 2019
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Cisplatin; Gemcitabine
- Indications Adenocarcinoma; Biliary cancer; Gallbladder cancer
- Focus Therapeutic Use
- 15 Aug 2019 Planned End Date changed from 1 Nov 2020 to 7 Jun 2021.
- 15 Aug 2019 Planned primary completion date changed from 1 Nov 2019 to 7 Dec 2019.
- 15 Aug 2019 Status changed from recruiting to active, no longer recruiting.